Kenvue Inc (FRA:J4D)
€ 21.21 0.715 (3.49%) Market Cap: 40.91 Bil Enterprise Value: 47.90 Bil PE Ratio: 39.72 PB Ratio: 4.33 GF Score: 25/100

Kenvue Inc at Consumer Analyst Group of New York (CAGNY) Virtual Conference Transcript

Feb 23, 2024 / 03:00PM GMT
Release Date Price: €17.4 (-0.57%)
Unidentified Participant

Kenvue would like to remind you that today's discussion will include forward-looking statements. These statements represent Kenvue's current beliefs about future events. Please refer to Kenvue's Registration Statement on Form S-1 and subsequent filings with the SEC for a discussion of factors that could cause the company's actual results to differ materially from these projections.

Additionally, today's discussion will include certain non-GAAP financial information. The company has posted on its Investor Relations website, investors.kenvue.com, a reconciliation of these measures to the nearest GAAP measure.

Unidentified Analyst

All right. Good morning. For our next session, I'm thrilled to welcome Kenvue to the stage for their first presentation to CAGNY as an independent public company. Tylenol, Motrin, Neutrogena, Aveeno, Listerine, Kenvue is home to brands that we all know and the consumers' trust.

And 2023 was an eventful year for the company. Starting the year as part of Johnson & Johnson, Kenvue navigated a dynamic

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot